-
Article
Computational immunogenomic approaches to predict response to cancer immunotherapies
Cancer immunogenomics is an emerging field that bridges genomics and immunology. The establishment of large-scale genomic collaborative efforts along with the development of new single-cell transcriptomic tech...
-
Article
Open AccessGenomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
In this article, we provide a comprehensive analysis of recent progress in the genetic characterisation of pleural mesothelioma, and the translation of these findings to clinical practice.
-
Article
Open AccessComprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) has a poor overall survival with few treatment options. Whole genome sequencing (WGS) combined with the immune features of MPM offers the prospect of identifying changes th...
-
Article
Open AccessCorrection to: Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
A correction to this paper has been published: https://doi.org/10.1007/s00262-021-02970-z
-
Article
Open AccessTumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
Surgical resection of cancer remains the frontline therapy for millions of patients annually, but post-operative recurrence is common, with a relapse rate of around 45% for non-small cell lung cancer. The tumo...
-
Article
Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life
Malignant pleural mesothelioma (MPM) is an incurable cancer and optimizing daily physical activity and quality of life are key goals of patient management. Little is known about the prevalence of pre-sarcopeni...
-
Article
Malignant Pleural Mesothelioma: an Update for Pulmonologists
Malignant pleural mesothelioma (MPM) is an incurable disease, and its global incidence is predicted to rise. The epidemiology is changing especially in developed countries where the increases in incidence cent...
-
Article
Open AccessTumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors
Pleural effusion (PE) is a common feature of malignant pleural mesothelioma. These effusions typically contain lymphocytes and malignant cells. We postulated that the PE would be a source of lymphocytes for an...
-
Article
Open AccessWhole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
Malignant mesothelioma (MM) is an aggressive cancer of the pleural and peritoneal cavities caused by exposure to asbestos. Asbestos-induced mesotheliomas in wild-type mice have been used extensively as a precl...
-
Article
Open AccessCalretinin as a blood-based biomarker for mesothelioma
Malignant mesothelioma (MM) is a deadly cancer mainly caused by previous exposure to asbestos. With a latency period up to 50 years the incidence of MM is still increasing, even in countries that banned asbest...
-
Article
Open AccessExcerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway
The goal of biomarker research is to identify clinically valid markers. Despite decades of research there has been disappointingly few molecules or techniques that are in use today. The “1st International NTNU...
-
Article
Open AccessSecreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
Malignant mesothelioma (MM) is a highly-aggressive heterogeneous malignancy, typically diagnosed at advanced stage. An important area of mesothelioma biology and progression is understanding intercellular comm...
-
Article
BAP1 mutations in mesothelioma: advances and controversies
Malignant mesothelioma (MM) is a fatal cancer of the pleural and peritoneal cavities caused predominantly by exposure to asbestos. Cohort studies suggest a genetic component to MM susceptibility. BAP1 is a tumour...
-
Article
Open AccessErratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
-
Article
Open AccessENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, caused primarily by exposure to asbestos. In this study, serum presence of mesothelioma-specific protein transcript variants of ecto-nicot...
-
Article
Open AccessConsistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma
The MexTAg transgenic mouse model of mesothelioma replicates many aspects of human mesothelioma, including induction by asbestos, pathogenicity and response to cytotoxic chemotherapy, despite high levels of th...
-
Article
Open AccessDiscovery of new biomarkers for malignant mesothelioma
Malignant mesothelioma is an asbestos-induced, aggressive tumour with limited treatment options and very poor outcome. Currently, there are no tumour biomarkers in widespread clinical use for this disease. Sol...
-
Article
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Marc Ladanyi and colleagues show that the nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma (MPM). They further show that knockdown of...
